EGFR Inhibitor-Associated Rash, Pruritus, Have Greatest Negative Impact on QOL

Share this content:
(ChemotherapyAdvisor) – Dermatologic adverse events lead to a diminished quality of life (QOL), with EGFR inhibitor-associated rash and pruritus “having the greatest negative impact,” investigators reported June 28 at the International Symposium on Supportive Care in Cancer, New York, NY.

Alyx C. Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY, and colleagues examined the effect of dermatologic adverse events on QOL in patients with cancer on conventional vs targeted therapies using a dermatologic-specific questionnaire.

A total of 283 patients completed the Skindex-16, a QOL questionnaire that measures effects on three domains, symptoms, emotions, and function. Patients were grouped into whether they had received targeted or nontargeted therapies.

Overall and sub-domain Skindex scores were evaluated and correlations of Skindex scores with type of anti-cancer therapy and number of and specific dermatologic adverse events were investigated.

A significant difference between patients receiving targeted vs nontargeted therapy was observed with regard to emotion (P=0.02) and overall (P =0.02) Skindex scores. EGFR inhibitor-associated rash had greater impact on symptoms (P=0.009), emotions (P<0.001), and function domain scores (P=0.01) as well as overall Skindex scores (P=0.001), as did pruritus (P<0.001, P=0.004, P=0.04, and P<0.001, respectively) compared with patients without these dermatologic adverse events.

The investigators recommended that to minimize QOL in patients with cancer who experience dermatologic adverse events, “emphasis should be placed on conducting randomized controlled trials to establish effective management strategies.”

The International Symposium on Supportive Care in Cancer is sponsored by the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs